Review Of Ampyra (dalfampridine) Cost, Side Effects, Dosage, And Prescribing Information For Multiple Sclerosis | Brianne Chin, PharmD | RxEconsult
Menus

All Health Articles

Ampyra (dalfampridine) Pricing, Dosing, Side Effects, and Benefits Category: Neurology: Multiple Sclerosis And More by - June 11, 2014 | Views: 48575 | Likes: 2 | Comment: 1  

What are contraindications with Ampyra?

Ampyra is contraindicated in patients with a history of seizures or with moderate or severe renal impairment (CrCl ≤ 50 mL/min), or a history of hypersensitivity to Ampyra or 4-aminopyridine (4-AP, fampridine) since the active ingredient is the same.

Interesting Facts about Ampyra

  • Ampyra is the only medication approved to improve walking in patients with multiple sclerosis. Approval was based on increased walking speed.
  • Do not take double or extra doses of Ampyra if a dose is missed. Adverse side effects, including seizures, are more frequent at higher doses.
  • Potential benefits of Ampyra should be weighed against the risks in patients who have mild-renal impairment.

What are Ampyra side effects?

The most common side effect of Ampyra is urinary tract infections (12%). Other common side effects include insomnia, nausea, dizziness, headache, indigestion, and back pain. Serious side effects of Ampyra include seizures and severe allergic reactions.

Can Ampyra be used in pregnancy?

Ampyra is pregnancy category C. There are no adequate studies of Ampyra in pregnant women.

What are Ampyra drug interactions?

There are no drug interactions that have been identified for Ampyra.

What is the cost of Ampyra?

The average wholesale price for a 2 month supply of 60 extended-release tablets is $1921.79. The average unit cost is $32.00 per extended-release tablet.

How to obtain prescription assistance for Ampyra

Acordia Therapeutics, Inc. offers Ampyra Patient Support Services (APSS) financial assistance programs . Please visit the Acordia Therapeutics, Inc. website Acordia Therapeutics, Inc assistance programs or call Acordia Therapeutics  Inc. at 1-888-881-1918.  

References

AMPYRA [prescribing information]. Athlone, Ireland: Acordia Therapeutics, Inc.; 2014.

FDA News Release: FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis; 2010. Accessed June 4, 2014.

FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine); 2012. Accessed June 11, 2014.

RED BOOK Online. AMPYRA. Truven Health Analytics, Inc.; 2014.

 
 
 
 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2020 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap